# US 2026/0297026 A1 · Usp30 inhibitors and uses thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2026/0297026 A1
- Document ID: US20260297026A1
- Status: Published application
- Kind: A1
- Application number: 19/692,596
- Filed: 2026-05-29
- Published: 2026-10-01
- Earliest claimed: 2019-09-11
- Assignees: Vincere Biosciences, Inc.
- Applicants: Vincere Biosciences, Inc.
- Inventors: Donna L. Romero; Michael Garrett Johnson; Andrew David Lee; Bahareh Behrouz; Edward Lawrence Fritzen, JR.
- Web page: https://patentgrep.com/patent/US20260297026A1

## CPC

- C07D 205/04: having no double bonds between ring members or between ring members and non-ring members
- C07C 317/36: with the nitrogen atoms of the amino groups bound to hydrogen atoms or to carbon atoms
- C07D 209/20: substituted additionally by nitrogen atoms, e.g. tryptophane
- C07D 211/58: attached in position 4
- C07D 213/72: Nitrogen atoms (nitro radicals C07D213/61)
- C07D 217/26: Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
- C07D 305/08: with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring atoms
- C07D 307/22: Nitrogen atoms not forming part of a nitro radical
- C07D 309/12: only hydrogen atoms and one oxygen atom directly attached to ring carbon atoms, e.g. tetrahydropyranyl ethers
- C07D 309/14: Nitrogen atoms not forming part of a nitro radical
- C07D 333/36: Nitrogen atoms
- C07D 405/12: linked by a chain containing hetero atoms as chain links
- C07D 471/04: Ortho-condensed systems
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- C07C: ACYCLIC OR CARBOCYCLIC COMPOUNDS

## Abstract

The present invention provides compounds, compositions thereof, and methods of using the same for the inhibition of USP30, and the treatment of USP30-mediated disorders.

## Claims

### Claim 1

A compound of formula I′:
or a pharmaceutically acceptable salt thereof, wherein:
Ring A is phenyl or a 5-6 membered heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur;
L1 is
each R is independently hydrogen or a C1-3 aliphatic group;
R1 is a 3-8 membered saturated or partially unsaturated monocyclic carbocyclic ring;
each R2 is independently halogen, —CF3, —CN, —C(O)NHR, —NO2, —NHR, —NHC(O)R, —NHS(O)2R, —N(R)2, —OR, or a C1-6 aliphatic group;
L2 is —C(O)N(R′)—;
R′ is hydrogen or a C1-3 aliphatic group;
L3 is —C(O)N(R″)—;
R″ is hydrogen or a C1-3 aliphatic group;
R3 is hydrogen or C1-3 aliphatic;
R4 is hydrogen or C1-3 aliphatic;
R5 is hydrogen or C1-3 aliphatic;
Ring B is phenyl or a 5-6 membered heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur;
each R6 is independently halogen, —CN, —NO2, —NHR, —N(R)2, —OR, or a C1-6 aliphatic group;
Ring C is phenyl or a 5-6 membered heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur;
each R7 is independently halogen, —CN, —NO2, —NHR, —N(R)2, —OR, or a C1-6 aliphatic group;
each of m, n, and p is independently 0, 1, 2, 3 or 4.

### Claim 2 (depends on 1)

The compound of claim 1 of formula II:
or a pharmaceutically acceptable salt thereof.

### Claim 3 (depends on 2)

The compound of claim 2, wherein Ring A is phenyl.

### Claim 4 (depends on 2)

The compound of claim 2, wherein Ring B is phenyl.

### Claim 5 (depends on 3)

The compound of claim 3, wherein Ring B is phenyl.

### Claim 6 (depends on 2)

The compound of claim 2, wherein Ring C is a 5-6 membered heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur.

### Claim 7 (depends on 3)

The compound of claim 3, wherein Ring C is a 5-6 membered heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur.

### Claim 8 (depends on 5)

The compound of claim 5, wherein Ring C is a 5-6 membered heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur.

### Claim 9 (depends on 2)

The compound of claim 2, wherein m, n, and p are 0.

### Claim 10 (depends on 3)

The compound of claim 3, wherein m, n, and p are 0.

### Claim 11 (depends on 8)

The compound of claim 8, wherein m, n, and p are 0.

### Claim 12 (depends on 1)

The compound of claim 1 of formula XVI-a or a pharmaceutically acceptable salt thereof:

### Claim 13 (depends on 1)

The compound of claim 1 of formula XVI-b or a pharmaceutically acceptable salt thereof:

### Claim 14

A compound selected from the following or a pharmaceutically acceptable salt thereof:

### Claim 15 (depends on 14)

The compound of claim 14, wherein the compound is the following or a pharmaceutically acceptable salt thereof:

### Claim 16 (depends on 14)

The compound of claim 14, wherein the compound is

### Claim 17 (depends on 14)

The compound of claim 14, wherein the compound is the following or a pharmaceutically acceptable salt thereof:

### Claim 18 (depends on 14)

The compound of claim 14, wherein the compound is

### Claim 19 (depends on 1)

A pharmaceutical composition comprising a compound according to claim 1, and a pharmaceutically acceptable carrier, adjuvant, or vehicle.

### Claim 20 (depends on 11)

A pharmaceutical composition comprising a compound according to claim 11, and a pharmaceutically acceptable carrier, adjuvant, or vehicle.

### Claim 21 (depends on 15)

A pharmaceutical composition comprising a compound according to claim 15, and a pharmaceutically acceptable carrier, adjuvant, or vehicle.

### Claim 22 (depends on 17)

A pharmaceutical composition comprising a compound according to claim 17, and a pharmaceutically acceptable carrier, adjuvant, or vehicle.

### Claim 23 (depends on 1)

A method of treating an USP30-mediated disorder, disease, or condition in a patient comprising administering to said patient a compound of claim 1.

### Claim 24 (depends on 14)

A method of treating an USP30-mediated disorder, disease, or condition in a patient comprising administering to said patient a compound of claim 14.
